Virtual Library

Start Your Search

J. Watanabe

Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P050 - Long-Term Survival of Stage IIIA-N2 NSCLC Patients with Interstitial Lung Diseases (ID 210)

      00:00 - 00:00  |  Author(s): J. Watanabe

      • Abstract

      Interstitial lung diseases (ILD) frequently occur in patients with lung cancer. The optimal treatment strategy for non-small-cell lung cancer (NSCLC) patients with ILD remains unclear. We reviewed the efficacy and safety of surgery, chemotherapy, and radiotherapy.

      We analyzed the medical records of patients with clinical stage IIIA-N2 NSCLC with ILD who were treated at our hospital between 2001 and 2016.

      505 patients with clinical stage IIIA-N2 NSCLC were included. Of these patients with ILD, treatments included surgical resection (S) in 14 patients, chemoradiotherapy (CRT) in 7 patients, palliative chemotherapy (C) in 7 patients and palliative radiotherapy in one patient.The median follow-up period was 38 months. The patients' characteristics were as follows S/CRT/C: male, 26/6/7 patients; median age (range), 69 (58-82)/69 (60-75)/69 (35-82) years. Of the S, pathological stage IA/IIA/IIB/IIIA/IIIB, 1/1/2/9/1 patients. The median progression-free survival times were 9.5 months (95% CI: 5.3-45.3 months) in S, 45.9 months (95% CI: 7.2 months- not reached [NR]) in CRT, and 5.0 months (95% CI: 0.5-10.5 months) in C. The median overall survival time were 33.3 months (95% CI: 9.8 months-NR) in S, 45.9 months (95% CI: 8.3 months-NR) in CRT, and 9.9 months (95% CI: 1.6-42.4 months) in C. One patient died within 1 month of surgical resection. Acute exacerbations of ILD (AE-ILD) were noted in 14 % of the patients; 3 patients after surgery and 1 patient after chemoradiotherapy.

      The surgery and chemoradiotherapy can be considered as a treatment option for selected patients with IIIA-N2 NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits.